Validation of a Paralimbic-Related Subcortical Brain Dysmaturation MRI Score in Infants with Congenital Heart Disease

William T Reynolds1, Jodie K Votava-Smith2,3, George Gabriel4

  • 1Department of Biomedical Informatics, University of Pittsburgh School of Medicine, Pittsburgh, PA 15206, USA.

PubMed

Insights

A new brain dysplasia score (BDS) detects subcortical abnormalities in infants with congenital heart disease (CHD), predicting developmental delays. The score was validated in a mouse model, suggesting common genetic causes for brain dysmaturation in CHD.

Area of Science:

  • Neuroscience
  • Developmental Biology
  • Medical Imaging

Background:

  • Infants with congenital heart disease (CHD) exhibit brain immaturity on MRI, previously assessed using cortical scores.
  • Paralimbic-related subcortical brain structures are crucial for development and function, yet their assessment in CHD infants is limited.

Purpose of the Study:

  • To develop and validate a semi-quantitative brain dysplasia score (BDS) for detecting subcortical abnormalities in infants with CHD.
  • To assess the BDS's ability to predict clinical outcomes and neurodevelopmental trajectories in CHD infants.
  • To validate the BDS in a preclinical mouse model of hypoplastic left heart syndrome.

Main Methods:

  • Structural MRIs from CHD infants (n=215) and healthy controls (n=92) were analyzed to derive the paralimbic-related subcortical BDS.
  • BDS was correlated with clinical factors, regional brain volumes, feeding status, and 18-month neurodevelopmental outcomes.
  • The BDS was validated in a CHD mouse model (Ohia) with identified genetic mutations (Sap130, Pchda9), using RNA-Seq for pathway analysis.

Main Results:

  • The BDS identified a high incidence of subcortical abnormalities (olfactory, cerebellar, hippocampal) in CHD infants compared to controls.
  • BDS correlated significantly with reduced cortical maturation, developmental delays, impaired language and feeding, and longer hospital stays.
  • The Ohia mouse model showed similar BDS findings, with RNA-Seq revealing altered neurodevelopmental and feeding pathways; Sap130 mutants had a more severe BDS.

Conclusions:

  • The developed BDS is a sensitive tool for identifying brain dysmaturation in CHD infants and predicting adverse clinical outcomes.
  • The findings in the Ohia mouse model suggest shared genetic mechanisms underlying paralimbic and subcortical abnormalities in human CHD.
  • The BDS offers a novel approach to characterizing brain abnormalities in CHD, potentially guiding early interventions and research into genetic etiologies.